Maastricht University
Maastricht, Netherlands
NCT Number: NCT02580513
This study will evaluate the effect of circadian misalignment on insulin sensitivity in healthy lean subjects in a randomized cross-over design. Subjects will be admitted to the research facility for two study periods of 3 and 3.5 days. In one of the study periods, the behavioral cycle will be shifted by 12 hours. Insulin sensitivity will be measured with a hyperinsulinemic euglycemic clamp.
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Not applicable
Maastricht, Netherlands
Recent evidence shows that misalignment of the circadian rhythm (e.g. by rotating shift work) impairs glucose metabolism markedly, possibly by decreasing insulin sensitivity in peripheral tissues and liver. Nowadays our society is indispensably connected to a lifestyle that allows wakefulness at every time of the 24 hours cycle. Social jetlag is a phenomenon that affects a large part of the general population, thus circadian misalignment extends far beyond those who are on a shift work schedule. Therefore, decreased insulin sensitivity in individuals affected by circadian misalignment may help to explain the increased prevalence of T2DM in night shift workers that has been found in epidemiological studies.
The study is an interventional randomized crossover trial in which each subject serves as it owns control. For the study, the investigators ask the subjects to participate in two study periods, one of 3 days length (control condition) and the other of 3.5 days length (misalignment condition). During the 3.5 day misalignment condition, subjects will shift their day-night rhythm by 12 hours, which will lead to maximal circadian misalignment. Insulin sensitivity will be measured by a hyperinsulinemic euglycemic clamp. Secondary parameters will include ex-vivo skeletal muscle mitochondrial function and whole-body energy metabolism.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 days after circadian misalignment and matched time in control arm.
Measured with hyperinsulinemic euglycemic clamp
Time frame: 2 days after circadian misalignment and matched time in control arm.
Time frame: 2 days after circadian misalignment and matched time in control arm.
Time frame: 1 and 2 days after circadian misalignment and matched times in control arm
Measured with high-resolution respirometry on permeabilized muscle fibers after muscle biopsy
Time frame: 1 and 2 days after circadian misalignment and matched times in control arm
Measured by indirect calorimetry
Time frame: 1.5 days after circadian misalignment and matched time in control arm
Measured by indirect calorimetry
Time frame: 1 and 2 days after circadian misalignment and matched times in control arm
Measured by qPCR
Time frame: 1 and 2 days after circadian misalignment and matched times in control arm
Measured by qPCR and Western Blotting
Time frame: 1 and 2 days after circadian misalignment and matched times in control arm
Measured by Western Blotting
Time frame: 1 and 2 days after circadian misalignment and matched times in control arm
Time frame: 1 day after circadian misalignment and matched time in control arm
Measured by a telemetric pill
Time frame: 1 day after circadian misalignment and matched time in control arm
Measured by skin temperature sensors
Time frame: 1 day after circadian misalignment and matched time in control arm
Measured by skin temperature sensors
Time frame: 1 day after circadian misalignment and matched time in control arm
Measured by heart rate monitor
Maastricht University Medical Center
Other
Impact of Circadian Misalignment on Insulin Sensitivity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00340132
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT03919877
Diabetes Mellitus, Diabetes Mellitus, Type 2
Stanford, California, United States
View Trial DetailsNCT03479671
Diabetes Mellitus, Diabetes Mellitus, Type 2
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT02266576
Diabetes Mellitus, Diabetes Mellitus, Type 2
San Jose, California, United States
View Trial Details